Aethlon Medical (NASDAQ:AEMD) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the medical equipment provider’s stock.

Separately, StockNews.com raised Aethlon Medical to a “sell” rating in a research report on Wednesday, February 19th.

Aethlon Medical Stock Performance

Shares of Aethlon Medical stock opened at $0.42 on Monday. The business’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.50. Aethlon Medical has a 52-week low of $0.24 and a 52-week high of $1.85. The firm has a market cap of $6.00 million, a PE ratio of -0.26 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. As a group, equities research analysts predict that Aethlon Medical will post -0.73 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new position in shares of Aethlon Medical during the 4th quarter worth approximately $25,000. Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Aethlon Medical during the 4th quarter worth approximately $26,000. Sassicaia Capital Advisers LLC acquired a new position in shares of Aethlon Medical during the 4th quarter worth approximately $31,000. Virtu Financial LLC acquired a new position in shares of Aethlon Medical during the 4th quarter worth approximately $81,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Aethlon Medical during the 4th quarter worth approximately $186,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.